Catalyst Pharmaceuticals, Inc. Forecasted to Post FY2024 Earnings of $0.85 Per Share (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share estimates for Catalyst Pharmaceuticals in a research report issued on Thursday, March 28th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will earn $0.85 per share for the year, down from their prior estimate of $0.97. Cantor Fitzgerald currently has a "Overweight" rating and a $34.00 target price on the stock. The consensus estimate for Catalyst Pharmaceuticals' current full-year earnings is $1.57 per share.

A number of other equities analysts also recently commented on CPRX. Bank of America initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They set a "buy" rating and a $23.00 target price for the company. Oppenheimer reiterated an "outperform" rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a research note on Wednesday. TheStreet upgraded shares of Catalyst Pharmaceuticals from a "c+" rating to a "b" rating in a research note on Tuesday, March 12th. Citigroup started coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 14th. They issued a "buy" rating and a $27.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and issued a $24.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $26.43.

Catalyst Pharmaceuticals Trading Down 2.0 %

Shares of CPRX stock traded down $0.33 on Friday, reaching $15.94. 1,172,375 shares of the stock were exchanged, compared to its average volume of 1,558,203. The business's 50 day moving average price is $15.02 and its 200 day moving average price is $14.20. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of 26.13, a PEG ratio of 1.14 and a beta of 0.92. Catalyst Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $18.22.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. The business had revenue of $110.57 million for the quarter, compared to analyst estimates of $105.78 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CPRX. FMR LLC lifted its position in shares of Catalyst Pharmaceuticals by 24.2% in the 2nd quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 822 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Catalyst Pharmaceuticals by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 39,594 shares of the biopharmaceutical company's stock valued at $532,000 after acquiring an additional 823 shares in the last quarter. Comerica Bank lifted its position in shares of Catalyst Pharmaceuticals by 2.2% in the 4th quarter. Comerica Bank now owns 46,780 shares of the biopharmaceutical company's stock valued at $786,000 after acquiring an additional 1,014 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of Catalyst Pharmaceuticals by 7.5% in the 2nd quarter. ProShare Advisors LLC now owns 15,087 shares of the biopharmaceutical company's stock valued at $203,000 after acquiring an additional 1,056 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in shares of Catalyst Pharmaceuticals by 7.8% in the 2nd quarter. Cetera Investment Advisers now owns 15,223 shares of the biopharmaceutical company's stock valued at $205,000 after acquiring an additional 1,096 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the company's stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total value of $411,000.00. Following the completion of the transaction, the insider now owns 124,433 shares in the company, valued at approximately $2,045,678.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 12.10% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.